Long-term prognostic significance of homocysteine in middle-aged and elderly

Julie Falkenberg Petersen; Bjørn Strøjer Larsen; Muhammad Sabbah; Olav Wendelboe Nielsen; Preman Kumarathurai; Ahmad Sajadieh

doi:10.3109/1354750X.2016.1160288

Long-term prognostic significance of homocysteine in middle-aged and elderly

Julie Falkenberg Petersen, Bjørn Strøjer Larsen, Muhammad Sabbah, Olav Wendelboe Nielsen, Preman Kumarathurai, Ahmad Sajadieh

Institut for Klinisk Medicin

9 Citationer (Scopus)

Abstract

Objective: We investigated the association among increased levels of plasma homocysteine (Hcy), all-cause mortality, and cardiovascular events. Methods: Hcy was measured in 670 middle-aged and elderly subjects with no previous manifest cardiovascular disease. The follow-up period was 15 years. Results: Subjects with Hcy ≥ 10.8 μmol/l (n = 231) had a significant higher incidence of all-cause mortality (p < 0.001) and CV events (p < 0.001) compared with subjects with Hcy < 10.8 μmol/l (n = 439). However, there was no association on high levels of Hcy and VTE events or stroke. Conclusion: Increased levels of Hcy are associated with all-cause mortality and CV events.

Originalsprog	Engelsk
Tidsskrift	Biomarkers
Vol/bind	21
Udgave nummer	6
Sider (fra-til)	490-6
Antal sider	7
ISSN	1354-750X
DOI	https://doi.org/10.3109/1354750X.2016.1160288
Status	Udgivet - 17 aug. 2016

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

10.3109/1354750X.2016.1160288

Citationsformater

@article{8a9e36fd9d31471d96c174e5973f0dc6,

title = "Long-term prognostic significance of homocysteine in middle-aged and elderly",

abstract = "Objective: We investigated the association among increased levels of plasma homocysteine (Hcy), all-cause mortality, and cardiovascular events. Methods: Hcy was measured in 670 middle-aged and elderly subjects with no previous manifest cardiovascular disease. The follow-up period was 15 years. Results: Subjects with Hcy ≥ 10.8 μmol/l (n = 231) had a significant higher incidence of all-cause mortality (p < 0.001) and CV events (p < 0.001) compared with subjects with Hcy < 10.8 μmol/l (n = 439). However, there was no association on high levels of Hcy and VTE events or stroke. Conclusion: Increased levels of Hcy are associated with all-cause mortality and CV events.",

keywords = "Aged, Biomarkers, Cardiovascular Diseases, Disease-Free Survival, Female, Follow-Up Studies, Homocysteine, Humans, Incidence, Kaplan-Meier Estimate, Male, Middle Aged, Prognosis, Proportional Hazards Models, Risk Factors, Journal Article",

author = "Petersen, {Julie Falkenberg} and Larsen, {Bj{\o}rn Str{\o}jer} and Muhammad Sabbah and Nielsen, {Olav Wendelboe} and Preman Kumarathurai and Ahmad Sajadieh",

year = "2016",

month = aug,

day = "17",

doi = "10.3109/1354750X.2016.1160288",

language = "English",

volume = "21",

pages = "490--6",

journal = "Biomarkers",

issn = "1354-750X",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Long-term prognostic significance of homocysteine in middle-aged and elderly

AU - Petersen, Julie Falkenberg

AU - Larsen, Bjørn Strøjer

AU - Sabbah, Muhammad

AU - Nielsen, Olav Wendelboe

AU - Kumarathurai, Preman

AU - Sajadieh, Ahmad

PY - 2016/8/17

Y1 - 2016/8/17

N2 - Objective: We investigated the association among increased levels of plasma homocysteine (Hcy), all-cause mortality, and cardiovascular events. Methods: Hcy was measured in 670 middle-aged and elderly subjects with no previous manifest cardiovascular disease. The follow-up period was 15 years. Results: Subjects with Hcy ≥ 10.8 μmol/l (n = 231) had a significant higher incidence of all-cause mortality (p < 0.001) and CV events (p < 0.001) compared with subjects with Hcy < 10.8 μmol/l (n = 439). However, there was no association on high levels of Hcy and VTE events or stroke. Conclusion: Increased levels of Hcy are associated with all-cause mortality and CV events.

AB - Objective: We investigated the association among increased levels of plasma homocysteine (Hcy), all-cause mortality, and cardiovascular events. Methods: Hcy was measured in 670 middle-aged and elderly subjects with no previous manifest cardiovascular disease. The follow-up period was 15 years. Results: Subjects with Hcy ≥ 10.8 μmol/l (n = 231) had a significant higher incidence of all-cause mortality (p < 0.001) and CV events (p < 0.001) compared with subjects with Hcy < 10.8 μmol/l (n = 439). However, there was no association on high levels of Hcy and VTE events or stroke. Conclusion: Increased levels of Hcy are associated with all-cause mortality and CV events.

KW - Aged

KW - Biomarkers

KW - Cardiovascular Diseases

KW - Disease-Free Survival

KW - Female

KW - Follow-Up Studies

KW - Homocysteine

KW - Humans

KW - Incidence

KW - Kaplan-Meier Estimate

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Proportional Hazards Models

KW - Risk Factors

KW - Journal Article

U2 - 10.3109/1354750X.2016.1160288

DO - 10.3109/1354750X.2016.1160288

M3 - Journal article

C2 - 27008914

SN - 1354-750X

VL - 21

SP - 490

EP - 496

JO - Biomarkers

JF - Biomarkers

IS - 6

ER -

Long-term prognostic significance of homocysteine in middle-aged and elderly

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater